Home Administrative Billing & Reimbursement BlueCard® Health and Wellness Medical PEAR portal Pharmacy Products Quality Management

Changes to precertification requirements for intravitreal VEGF products effective January 1, 2020

October 2, 2019

Effective January 1, 2020, Avastin® and its biosimilars (i.e., Mvasi™, Zirabev™) will be the preferred intravitreal vascular endothelial growth factor (VEGF) products for Independence commercial and Medicare Advantage members.* We will continue to cover the other intravitreal VEGF products, but they will be approved only for members who have demonstrated failure, contraindication, or intolerance to Avastin or an Avastin biosimilar.

Currently, there are six intravitreal VEGF products that treat ophthalmologic conditions such as neovascular (wet or exudative) advanced macular degeneration and diabetic macular edema:

  • Avastin® (bevacizumab)
  • Eylea® (aflibercept)
  • Lucentis® (ranibizumab)
  • Macugen® (pegaptanib)
  • Mvasi™ (bevacizumab-awwb)
  • Zirabev™ (bevacizumab-bvzr)

Updates to VEGF precertification requirements for ophthalmologic indications

Requests for intravitreal Avastin or its biosimilars do not require precertification approval from Independence.

All new requests for Eylea, Lucentis, or Macugen received on or after January 1, 2020, will require precertification approval for all Independence members.

Members who have received Eylea, Lucentis, or Macugen in the past 12 months will continue to be approved to receive treatment with these drugs.

Learn more

In October, Independence will send letters to affected providers to notify them of these changes.

Additional information about this change will be communicated in future Partners in Health UpdateSM articles, and our commercial and Medicare Advantage medical policies will be updated to reflect these new requirements.

These changes will also be reflected in an updated precertification requirement list, which will be posted to our website.

*As additional biosimilars to Avastin receive approval from the U.S. Food and Drug Administration, these products will also be designated as preferred products for Independence members.


This content was prepared for the Provider News Center and may not be reproduced in any way without the express written permission of Independence Blue Cross. Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association.
Connect with us     Facebook     Twitter     Flickr     YouTube     Walk the Talk    Independence Pinterest    Independence LinkedIn    Independence Instagram Site Map        Anti-Fraud        Privacy Policy        Legal        Disclaimer
© 2023 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.